KIZOO Technology Capital primarily focuses on seed and follow-on investments in rejuvenation biotechnology startups, aiming to reverse age-related damage at the cellular and molecular level. They provide both financial backing and mentoring to young companies in this emerging field.
40% of their portfolio is in HR & Talent. Their most common stage is series-a (40% of deals). Average disclosed round size is $13.3M (across 4 rounds with reported amounts).
Portfolio
5
Fund Size
$352M
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Mogling Bio | Seed | — | Oct 2022 |
 Elevian | Series A | $15M | Nov 2020 |
 Staffbase | Series C | $23M | Jul 2019 |
 SuitePad | Seed | $3.3M | Feb 2016 |
| Staffbase | Series A | $12M | — |
Top Co-Investors
Insight Partners2 shared
e.ventures2 shared
Capnamic Ventures2 shared
Prime Movers Lab1 shared
Bold Capital Partners1 shared
WTI1 shared
Target Global1 shared
Last updated: 18 March 2026